Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Paediatric drugs 2022-11, Vol.24 (6), p.603-655
Hauptverfasser: Ziesenitz, Victoria C., Welzel, Tatjana, van Dyk, Madelé, Saur, Patrick, Gorenflo, Matthias, van den Anker, Johannes N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 655
container_issue 6
container_start_page 603
container_title Paediatric drugs
container_volume 24
creator Ziesenitz, Victoria C.
Welzel, Tatjana
van Dyk, Madelé
Saur, Patrick
Gorenflo, Matthias
van den Anker, Johannes N.
description Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.
doi_str_mv 10.1007/s40272-022-00514-1
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9592650</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A723971020</galeid><sourcerecordid>A723971020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-62b4a2656b856ed90225e2f4500d21102421113257911009bbf7fdcfa27764703</originalsourceid><addsrcrecordid>eNp9UU1vEzEQtRAVLYU_wAFZ4rzF9q7XMQekKJQSKWoRhQMny-sdJ66ydmo7Qfn3dZo2UKlClr9m3ryZeYPQO0rOKCHiY2oIE6wirGzCaVPRF-iEUiErRqh8ef9uKj4So2P0OqUbQqioW_YKHdct4XUtxQman1vrjDZbrH2Pr7WFvMXB4svr8fRLws7jqbfa5_QJj_EkDKsIC_DJbQD_gI2DPztwXgCeuQxR53WER8t3nTJmBP8GHdMbdGT1MsHbh_sU_fp6_nPyrZpdXUwn41lleENz1bKu0azlbTfiLfSy9MaB2YYT0jNKCWvKSWvGhSw_IrvOCtsbq5kQbSNIfYo-73lX626A3oDPUS_VKrpBx60K2qmnHu8Wah42SnJZ8u4IPjwQxHC7hpTVTVhHX2pWReySVdZFxQNqrpegnLehkJnBJaPGghVlS6k7rrNnUGX1MDgTPFhX7E8C2D7AxJBSBHsonBK1m7naz1wVXdT9zBUtQe__bfkQ8jjkAqj3gFRcfg7xb0v_ob0DvpuzEQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729119317</pqid></control><display><type>article</type><title>Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ziesenitz, Victoria C. ; Welzel, Tatjana ; van Dyk, Madelé ; Saur, Patrick ; Gorenflo, Matthias ; van den Anker, Johannes N.</creator><creatorcontrib>Ziesenitz, Victoria C. ; Welzel, Tatjana ; van Dyk, Madelé ; Saur, Patrick ; Gorenflo, Matthias ; van den Anker, Johannes N.</creatorcontrib><description>Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.</description><identifier>ISSN: 1174-5878</identifier><identifier>EISSN: 1179-2019</identifier><identifier>DOI: 10.1007/s40272-022-00514-1</identifier><identifier>PMID: 36053397</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Acids ; Adolescent ; Age groups ; Anti-Inflammatory Agents ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Aspirin ; Aspirin - adverse effects ; Babies ; Celecoxib - adverse effects ; Child ; Chronic Disease ; Complications and side effects ; Diclofenac ; Drug dosages ; Fever ; Flurbiprofen ; Health aspects ; Humans ; Ibuprofen ; Infant ; Infants ; Internal Medicine ; Ketoprofen ; Ketorolac ; Medical records ; Medicine ; Medicine &amp; Public Health ; Meloxicam ; Metabolism ; Naproxen - therapeutic use ; Niflumic Acid ; Nonsteroidal anti-inflammatory drugs ; Pain ; Pain - drug therapy ; Patient outcomes ; Pediatrics ; Pharmacotherapy ; Review ; Review Article ; Teenagers</subject><ispartof>Paediatric drugs, 2022-11, Vol.24 (6), p.603-655</ispartof><rights>The Author(s) 2022. corrected publication 2022</rights><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 Springer</rights><rights>Copyright Springer Nature B.V. Nov 2022</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-62b4a2656b856ed90225e2f4500d21102421113257911009bbf7fdcfa27764703</citedby><cites>FETCH-LOGICAL-c541t-62b4a2656b856ed90225e2f4500d21102421113257911009bbf7fdcfa27764703</cites><orcidid>0000-0003-2836-4212</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40272-022-00514-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40272-022-00514-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36053397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ziesenitz, Victoria C.</creatorcontrib><creatorcontrib>Welzel, Tatjana</creatorcontrib><creatorcontrib>van Dyk, Madelé</creatorcontrib><creatorcontrib>Saur, Patrick</creatorcontrib><creatorcontrib>Gorenflo, Matthias</creatorcontrib><creatorcontrib>van den Anker, Johannes N.</creatorcontrib><title>Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years</title><title>Paediatric drugs</title><addtitle>Pediatr Drugs</addtitle><addtitle>Paediatr Drugs</addtitle><description>Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.</description><subject>Acids</subject><subject>Adolescent</subject><subject>Age groups</subject><subject>Anti-Inflammatory Agents</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Aspirin</subject><subject>Aspirin - adverse effects</subject><subject>Babies</subject><subject>Celecoxib - adverse effects</subject><subject>Child</subject><subject>Chronic Disease</subject><subject>Complications and side effects</subject><subject>Diclofenac</subject><subject>Drug dosages</subject><subject>Fever</subject><subject>Flurbiprofen</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Ibuprofen</subject><subject>Infant</subject><subject>Infants</subject><subject>Internal Medicine</subject><subject>Ketoprofen</subject><subject>Ketorolac</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meloxicam</subject><subject>Metabolism</subject><subject>Naproxen - therapeutic use</subject><subject>Niflumic Acid</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Pain</subject><subject>Pain - drug therapy</subject><subject>Patient outcomes</subject><subject>Pediatrics</subject><subject>Pharmacotherapy</subject><subject>Review</subject><subject>Review Article</subject><subject>Teenagers</subject><issn>1174-5878</issn><issn>1179-2019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UU1vEzEQtRAVLYU_wAFZ4rzF9q7XMQekKJQSKWoRhQMny-sdJ66ydmo7Qfn3dZo2UKlClr9m3ryZeYPQO0rOKCHiY2oIE6wirGzCaVPRF-iEUiErRqh8ef9uKj4So2P0OqUbQqioW_YKHdct4XUtxQman1vrjDZbrH2Pr7WFvMXB4svr8fRLws7jqbfa5_QJj_EkDKsIC_DJbQD_gI2DPztwXgCeuQxR53WER8t3nTJmBP8GHdMbdGT1MsHbh_sU_fp6_nPyrZpdXUwn41lleENz1bKu0azlbTfiLfSy9MaB2YYT0jNKCWvKSWvGhSw_IrvOCtsbq5kQbSNIfYo-73lX626A3oDPUS_VKrpBx60K2qmnHu8Wah42SnJZ8u4IPjwQxHC7hpTVTVhHX2pWReySVdZFxQNqrpegnLehkJnBJaPGghVlS6k7rrNnUGX1MDgTPFhX7E8C2D7AxJBSBHsonBK1m7naz1wVXdT9zBUtQe__bfkQ8jjkAqj3gFRcfg7xb0v_ob0DvpuzEQ</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Ziesenitz, Victoria C.</creator><creator>Welzel, Tatjana</creator><creator>van Dyk, Madelé</creator><creator>Saur, Patrick</creator><creator>Gorenflo, Matthias</creator><creator>van den Anker, Johannes N.</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2836-4212</orcidid></search><sort><creationdate>20221101</creationdate><title>Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years</title><author>Ziesenitz, Victoria C. ; Welzel, Tatjana ; van Dyk, Madelé ; Saur, Patrick ; Gorenflo, Matthias ; van den Anker, Johannes N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-62b4a2656b856ed90225e2f4500d21102421113257911009bbf7fdcfa27764703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acids</topic><topic>Adolescent</topic><topic>Age groups</topic><topic>Anti-Inflammatory Agents</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Aspirin</topic><topic>Aspirin - adverse effects</topic><topic>Babies</topic><topic>Celecoxib - adverse effects</topic><topic>Child</topic><topic>Chronic Disease</topic><topic>Complications and side effects</topic><topic>Diclofenac</topic><topic>Drug dosages</topic><topic>Fever</topic><topic>Flurbiprofen</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Ibuprofen</topic><topic>Infant</topic><topic>Infants</topic><topic>Internal Medicine</topic><topic>Ketoprofen</topic><topic>Ketorolac</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meloxicam</topic><topic>Metabolism</topic><topic>Naproxen - therapeutic use</topic><topic>Niflumic Acid</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Pain</topic><topic>Pain - drug therapy</topic><topic>Patient outcomes</topic><topic>Pediatrics</topic><topic>Pharmacotherapy</topic><topic>Review</topic><topic>Review Article</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ziesenitz, Victoria C.</creatorcontrib><creatorcontrib>Welzel, Tatjana</creatorcontrib><creatorcontrib>van Dyk, Madelé</creatorcontrib><creatorcontrib>Saur, Patrick</creatorcontrib><creatorcontrib>Gorenflo, Matthias</creatorcontrib><creatorcontrib>van den Anker, Johannes N.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Paediatric drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ziesenitz, Victoria C.</au><au>Welzel, Tatjana</au><au>van Dyk, Madelé</au><au>Saur, Patrick</au><au>Gorenflo, Matthias</au><au>van den Anker, Johannes N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years</atitle><jtitle>Paediatric drugs</jtitle><stitle>Pediatr Drugs</stitle><addtitle>Paediatr Drugs</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>24</volume><issue>6</issue><spage>603</spage><epage>655</epage><pages>603-655</pages><issn>1174-5878</issn><eissn>1179-2019</eissn><abstract>Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36053397</pmid><doi>10.1007/s40272-022-00514-1</doi><tpages>53</tpages><orcidid>https://orcid.org/0000-0003-2836-4212</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1174-5878
ispartof Paediatric drugs, 2022-11, Vol.24 (6), p.603-655
issn 1174-5878
1179-2019
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9592650
source MEDLINE; SpringerLink Journals
subjects Acids
Adolescent
Age groups
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Aspirin
Aspirin - adverse effects
Babies
Celecoxib - adverse effects
Child
Chronic Disease
Complications and side effects
Diclofenac
Drug dosages
Fever
Flurbiprofen
Health aspects
Humans
Ibuprofen
Infant
Infants
Internal Medicine
Ketoprofen
Ketorolac
Medical records
Medicine
Medicine & Public Health
Meloxicam
Metabolism
Naproxen - therapeutic use
Niflumic Acid
Nonsteroidal anti-inflammatory drugs
Pain
Pain - drug therapy
Patient outcomes
Pediatrics
Pharmacotherapy
Review
Review Article
Teenagers
title Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A27%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20NSAIDs%20in%20Infants:%20A%20Comprehensive%20Review%20of%20the%20Literature%20of%20the%20Past%2020%20Years&rft.jtitle=Paediatric%20drugs&rft.au=Ziesenitz,%20Victoria%20C.&rft.date=2022-11-01&rft.volume=24&rft.issue=6&rft.spage=603&rft.epage=655&rft.pages=603-655&rft.issn=1174-5878&rft.eissn=1179-2019&rft_id=info:doi/10.1007/s40272-022-00514-1&rft_dat=%3Cgale_pubme%3EA723971020%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2729119317&rft_id=info:pmid/36053397&rft_galeid=A723971020&rfr_iscdi=true